Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia

Journal of Oral Pathology and Medicine

Volumn 42, Issue 5, 2013, Pages 382-388

  Shimanishi, Makoto ^a   Ogi, Kazuhiro ^a   Sogabe, Yohei ^a   Kaneko, Takeshi ^a   Dehari, Hironari ^a   Miyazaki, Akihiro ^a   Hiratsuka, Hiroyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin (CDDP); Glucose transporter 1(GLUT 1); Hypoxia; Oral squamous cell carcinoma

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; COMPLEMENTARY DNA; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SENSITIZATION; FLOW CYTOMETRY; GENE CONTROL; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TONGUE CARCINOMA; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOUTH NEOPLASMS; RNA, SMALL INTERFERING; TONGUE NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84876726278     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12028     Document Type: Article

References (30)

1. Rogers SN. Quality of life for head and neck cancer patients-has treatment planning altered? Oral Oncol 2009; 45: 435-9.
2. Osaki T, Hirota J, Yoneda K, Yamamoto T, Ueta E. Distribution of surviving tumor cells after chemoradiotherapy in tongue and floor of mouth carcinomas. Head Neck 1994; 16: 218-26.
3. Zagórska A, Dulak J. HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol 2004; 51: 563-85.
4. Ruas JL, Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin Cell Dev Biol 2005; 16: 514-22.
5. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003; 44: 198-206.
6. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009; 50: 74S-88S.
7. Esterman A, Greco MA, Mitani Y, Finlay TH, Ismail-Beigi F, Dancis J. The effect of hypoxia on human trophoblast in culture: morphology, glucose transport and metabolism. Placenta 1997; 18: 129-36.
8. Hayashi M, Sakata M, Takeda T, et al. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions in trophoblast-derived cells. J Endocrinol 2004; 183: 145-54.
9. Ohba S, Fujii H, Ito S, et al. Overexpression of GLUT-1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis. J Oral Pathol Med 2010; 39: 74-8.
10. Jonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006; 79: 288-97.
11. Kunkel M, Moergel M, Stockinger M, et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 2007; 43: 796-803.
12. Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 1993; 5: 667-75.
13. Kohno K, Uchiumi T, Niina I, et al. Transcription factors and drug resistance. Eur J Cancer 2005; 41: 2577-86.
14. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.
15. Jordan P, Carmo-Fonseca M. Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res 1998; 26: 2831-6.
16. Komatsu M, Sumizawa T, Mutoh M, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000; 60: 1312-6.
17. Malhotra R, Lin Z, Vincenz C, Brosius FC III. Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation by glucose. Am J Physiol Cell Physiol 2001; 5: 1596-603.
18. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124: 269-70.
19. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
20. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654-62.
21. Jing Li, Mingxia Shi, Ying Cao, et al. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun 2006; 4: 1341-51.
22. Welsh S, Williams R, Kirkpatrick L, et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004; 3: 233-44.
23. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002; 20: 680-7.
24. Chen J, Zhao S, Nakada K, et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003; 162: 1283-91.
25. Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel MT. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 2008; 15: 2656-63.
26. Azuma M, Tamatani T, Ashida Y, Takashima R, Harada K, Sato M. Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF-kappaB-suppressed pathway. Oral Oncol 2003; 3: 282-9.
27. Mese H, Sasaki A, Nakayama S, et al. Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line. Anticancer Res 2001; 2: 1029-33.
28. Yeo EJ, Chun YS, Cho YS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95: 516-25.
29. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65: 613-21.
30. Koshiji M, Kageyama Y, Pete EA, et al. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23: 1949-56.